Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) from a buy rating to a hold rating in a research report sent to investors on Tuesday, November 7th.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

Several other research analysts also recently commented on KPTI. Royal Bank Of Canada reaffirmed a buy rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Robert W. Baird reissued a buy rating on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. Jefferies Group LLC reissued a buy rating on shares of Karyopharm Therapeutics in a research report on Friday, October 13th. Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the stock a buy rating in a research report on Thursday, October 12th. Finally, ValuEngine lowered Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Thursday, August 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $17.33.

Karyopharm Therapeutics (NASDAQ KPTI) traded down $0.10 during trading hours on Tuesday, hitting $11.23. 33,588 shares of the stock were exchanged, compared to its average volume of 241,926. Karyopharm Therapeutics has a 12 month low of $7.48 and a 12 month high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). sell-side analysts anticipate that Karyopharm Therapeutics will post -2.59 earnings per share for the current year.

In other Karyopharm Therapeutics news, SVP Christopher Brett Primiano sold 4,958 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $11.25, for a total value of $55,777.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mansoor Raza Mirza sold 2,882 shares of the stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $11.00, for a total value of $31,702.00. Following the transaction, the director now owns 2,882 shares of the company’s stock, valued at $31,702. The disclosure for this sale can be found here. Insiders sold a total of 15,653 shares of company stock valued at $174,728 over the last 90 days. 14.71% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Karyopharm Therapeutics by 31.1% during the second quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock valued at $14,675,000 after purchasing an additional 384,658 shares in the last quarter. Teachers Advisors LLC raised its position in Karyopharm Therapeutics by 915.0% during the first quarter. Teachers Advisors LLC now owns 420,563 shares of the company’s stock valued at $5,400,000 after acquiring an additional 379,127 shares in the last quarter. JPMorgan Chase & Co. raised its position in Karyopharm Therapeutics by 753.5% during the third quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock valued at $3,342,000 after acquiring an additional 271,208 shares in the last quarter. Candriam Luxembourg S.C.A. raised its position in Karyopharm Therapeutics by 154.7% during the second quarter. Candriam Luxembourg S.C.A. now owns 438,000 shares of the company’s stock valued at $3,964,000 after acquiring an additional 266,000 shares in the last quarter. Finally, Tekla Capital Management LLC raised its position in Karyopharm Therapeutics by 25.0% during the second quarter. Tekla Capital Management LLC now owns 756,679 shares of the company’s stock valued at $6,848,000 after acquiring an additional 151,455 shares in the last quarter. Hedge funds and other institutional investors own 59.52% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Downgraded to Hold at Zacks Investment Research” was first published by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://baseballnewssource.com/markets/zacks-investment-research-downgrades-karyopharm-therapeutics-inc-kpti-to-hold/1763317.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.